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        Huntington  ’  s disease (HD) is an incurable, auto-
somal dominantly inherited neurodegenerative 
condition caused by a CAG repeat expansion 
in the gene encoding huntingtin. The mutant 
protein causes neuronal dysfunction and death 
resulting in the cardinal disease features of move-
ment disorder, cognitive decline, and psychiatric 
symptoms (  1  ). Huntingtin is expressed ubiqui-
tously (  2  ), and HD includes several abnormal-
ities outside the central nervous system (CNS), 
including up-regulation of immune proteins 
(  3  –  6  ). The interactions between CNS pathol-
ogy and changes detectable in peripheral tissues 
in HD are poorly understood but may be of 
importance in measuring or slowing disease pro-
gression. We previously demonstrated evidence 
of immune activation in peripheral plasma in 
manifest HD using proteomic profi  ling (  6  ), but 
no signifi  cant diff  erences between controls and 
premanifest mutation carriers have previously 
been shown. 
  The nature of the immune activation in 
HD remains incompletely explored. It is not 
known whether the innate or adaptive arm of 
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  Huntington  ’  s disease (HD) is an inherited neurodegenerative disorder characterized by both 
neurological and systemic abnormalities. We examined the peripheral immune system and 
found widespread evidence of innate immune activation detectable in plasma throughout 
the course of HD. Interleukin 6 levels were increased in HD gene carriers with a mean 
of 16 years before the predicted onset of clinical symptoms. To our knowledge, this is 
the earliest plasma abnormality identifi  ed in HD. Monocytes from HD subjects expressed 
mutant huntingtin and were pathologically hyperactive in response to stimulation, sug-
gesting that the mutant protein triggers a cell-autonomous immune activation. A similar 
pattern was seen in macrophages and microglia from HD mouse models, and the cerebro-
spinal fl  uid and striatum of HD patients exhibited abnormal immune activation, suggesting 
that immune dysfunction plays a role in brain pathology. Collectively, our data suggest 
parallel central nervous system and peripheral pathogenic pathways of immune activation 
in HD. 
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    RESULTS   
  We collected 194 plasma samples from HD mutation carriers 
ranging from premanifest to moderate HD and from control sub-
jects (Table S1, available at http://www.jem.org/cgi/content/
full/jem.20080178/DC1) and quantifi  ed levels of key infl  am-
matory and immunomodulatory molecules using multiplex 
sandwich ELISAs and single radial immunodiff  usion assays. 
We found an altered profi  le of cytokine levels in HD patients 
(  Fig. 1  ).   The most striking increases across subject groups from 
controls to progressing disease were in IL-6 and IL-8 (P   <   
0.0001 in each case). In addition, IL-4, IL-10, and TNF-     
levels increased signifi  cantly with disease progression (  Fig. 1 B  ). 
Moreover, IL-6 levels were signifi  cantly increased in premani-
fest subjects with an estimated mean of 16 yr until motor onset 
(  Fig. 1 A  ) (  14  ). Interestingly, the cytokines that were increased 
earliest in the disease course (IL-6 and IL-8) are involved in the 
innate immune response (  15  ). IL-10 and IL-4, antiinfl  am-
matory cytokines involved in the adaptive immune response, 
increased signifi  cantly in moderate stage disease. There was no 
diff  erence in levels of Igs (IgG, IgA, or IgM) at any disease 
the immune system, or both, is activated in HD, and the 
alterations in each immunomodulatory cytokine at each dis-
ease stage are unknown. The cause of the immune activa-
tion peripherally is also unknown. IL-6, which triggers the 
acute phase response, is produced primarily by monocytes 
and lymphocytes, but this could be due to dysfunction of 
these cells caused by expression of mutant huntingtin (i.e., a 
cell-autonomous eff  ect) or in response to infl  ammation-trig-
gering events outside these cells, such as huntingtin-induced 
tissue damage or the mutant protein itself being interpreted as 
an antigen (i.e., non  –  cell-autonomous pathways). Of inter-
est in this respect is the fi  nding that the I    B kinase/NF-    B 
signaling pathway that triggers IL-6 release is up-regulated 
by mutant huntingtin, and this may contribute to neuro-
toxicity (  7  ). 
  Critically, the relationship between peripheral infl  amma-
tion and CNS pathology in HD is unknown. Certain infl  am-
matory proteins, such as complement proteins and clusterin, 
are also up-regulated both peripherally and in the brain in HD 
(  6, 8, 9  ). In vivo imaging, in vitro and postmortem studies 
have shown that microglia, the CNS counterpart of macro-
phages, are activated in premanifest (  10  ) and manifest HD 
(  11  ), that microglial activation correlates with disease severity 
(  12  ), and that mutant huntingtin is expressed in microglia (  13  ). 
Thus, infl  ammation is an established, though incompletely 
understood, feature of HD with likely pathogenic importance. 
Infl  ammatory changes in the CNS and peripheral tissues in 
HD may be due to independent eff  ects of mutant huntingtin 
in both compartments, causing analogous derangements cen-
trally and peripherally; or infl  ammatory activation may begin 
peripherally and spread to the CNS, or vice versa, through the 
passage of immunomodulatory molecules across the blood  –
  brain barrier. 
  Insights into CNS and peripheral immune system inter-
actions in HD may provide new biomarkers and improve 
knowledge of key pathogenic mechanisms, possibly leading 
to novel therapeutic approaches. The present work seeks to 
elucidate further the nature of the peripheral infl  ammatory 
activation in HD through quantifi  cation of levels of key in-
fl  ammatory and immunomodulatory molecules in human 
plasma, and serum from three diff  erent mouse models of HD. 
To investigate possible links between peripheral infl  amma-
tion and neuronal dysfunction, we examined correlations be-
tween individual infl  ammatory molecules and clinical features 
of HD. We used targeted transcription profi  ling to examine 
expression of key immunomodulatory proteins in the HD 
striatum to determine whether the infl  ammatory activation 
seen peripherally is mirrored in the CNS. We examined ex-
pression of huntingtin in its WT and mutant forms in human 
monocytes to investigate the possibility that the immune 
activation is due to a disease-related cell-autonomous dys-
function of these cells. We confi  rmed this with functional 
studies of human monocytes, and macrophages and microg-
lia from HD mouse models, demonstrating that there is 
disease-related dysfunction of CNS and peripheral infl  am-
matory cells in HD. 
    Figure 1.         Altered immune profi  le peripherally in HD.  (A)  Multiplex 
ELISA quantifi  cation of cytokine levels in plasma from HD patients (pre-
manifest, early and moderate HD stages) compared with control subjects. 
Graphs show mean concentrations with standard error bars. Signifi  cant 
differences between individual groups are shown (ANOVA with post-hoc 
Tukey HSD test). (B) The overall trend for increasing levels of cytokines 
across all groups, analyzed using linear regression, was highly signifi  cant 
for IL-6 and IL-8 and signifi  cant for IL-4, IL-10, TNF-    , and IL-5. R-values 
(partial correlation coeffi  cients) are corrected for age and sex. *, P   <   0.05; 
**, P   <   0.01; ***, P   <   0.001; ****, P   <   0.0001.     JEM VOL. 205, August 4, 2008 
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IL-8, and IL-10 best discriminated all HD expansion carriers 
(premanifest and manifest) from controls (AUC 0.82). IL-6, 
IL-8, and IL-10 together best discriminated between pre-
manifest and manifest HD patients (AUC 0.85). 
  IL-6 triggers the acute phase response and is produced pri-
marily by monocytes/macrophages and lymphocytes (  15  ). To 
defi  ne the possible source of peripheral cytokines, we purifi  ed 
monocytes from whole blood from HD patients and control 
subjects by fl  ow cytometric and magnetic sorting. Using RT  –
  quantitative PCR (QPCR), we found monocytes from HD 
patients to express mutant huntingtin (  Fig. 5, A and B  ).   
  We then stimulated isolated monocytes with LPS and 
found that monocytes from premanifest HD mutation car-
riers behave abnormally, displaying excess IL-6 production 
compared with cells from control subjects (  Fig. 6 A  ).   Mutant 
huntingtin thus appears to produce functional overactivity of 
monocytes. We stimulated isolated macrophages from the 
yeast artifi  cial chromosome (YAC)128 mouse model of HD 
with LPS. Echoing the results seen in human HD monocytes, 
macrophages from the YAC128 responded with enhanced 
stage (  Fig. 2  ), arguing against widespread activation of the 
adaptive humoral immune system.   
  We then examined correlations between these cytokine 
changes and clinical characteristics. Plasma IL-8 levels in-
creased markedly with disease progression (  Fig. 1  ) and corre-
lated with clinical measures of HD. Levels of IL-8 correlated 
positively with worsening disease, as demonstrated by unifi  ed 
HD rating scale (UHDRS) (  16  ) chorea scores (R =     0.37; 
P   <   0.01) and total motor scores (R = 0.27; P   <   0.05), as well 
as negatively with total functional capacity (TFC) scores 
where lower scores indicate more severe disease (R =     0.28; 
P   <   0.05) (  Fig. 3 A  ).   TNF-     levels in plasma correlated with 
UHDRS chorea scores (R = 0.28; P   <   0.01) and UHDRS 
motor scores (R = 0.26; P   <   0.05) (  Fig. 3 B  ); a negative cor-
relation with TFC was seen that approached statistical signifi  -
cance (R =     0.20; P = 0.07). 
  Objective markers of HD progression are needed to facil-
itate the conduct of clinical trials of disease-modifying thera-
pies in HD (  17  ). We used stepwise logistic regression analysis 
to construct receiver operating characteristic (ROC) curves 
that demonstrated a strong ability of combinations of plasma 
cytokine levels to discriminate between disease groups (  Fig. 4  ).   
We found that a combination of IL-6, IL-10, and IL-5 best 
discriminated between premanifest HD and controls with an 
area under the curve (AUC) of 0.81. A combination of IL-6, 
    Figure 2.         Plasma Ig levels are unchanged in HD.   Quantifi  cation of 
plasma IgG, IgA, and IgM by single radial immunodiffusion assays re-
vealed no difference in Ig levels across disease stages, arguing against 
widespread activation of the adaptive immune system. Graphs show 
mean concentration standard error bars.     
    Figure 3.         Correlations between plasma cytokine levels and clinical 
severity scores in premanifest and manifest HD gene carriers.   Levels 
of (A) IL-8 and (B) TNF-     correlated with worsening disease as demon-
strated by increasing UHDRS chorea score and UHDRS total motor score 
and decreasing total functional capacity score.     
    Figure 4.         ROC curves demonstrating the ability of different com-
binations of plasma cytokine levels to discriminate between subject 
groups.   In a ROC curve plot, the   “  true positive  ”   diagnosis rate (sensitivity) 
is plotted against the   “  false positive  ”   diagnosis rate (1-specifi  city) for a 
test with a binary outcome. The AUC summarizes the discrimination of 
the test, i.e., its ability to classify cases correctly. A perfect test would have 
an AUC of 1; a worthless test would have an AUC of 0.5. AUC values may 
be classifi  ed as follows: 0.9  –  1, excellent; 0.8  –  0.9, good; 0.7  –  0.8, fair; 0.6  –
  0.7, poor; 0.5  –  0.6, fail (reference   36  ). For the present analysis, optimum 
combinations were identifi  ed by stepwise logistic regression analysis us-
ing a threshold of P = 0.05 for each cytokine removed from the model. A 
combination of IL-6, IL-10, and IL-5 best discriminated between controls 
and premanifest HD; a combination of IL-6, IL-8, and IL-10 best discrimi-
nated manifest from premanifest HD; and a combination of IL-6, IL-8, and 
IL-10 best discriminated controls from HD gene carriers (both premanifest 
and  manifest).   1872 IMMUNE  ACTIVATION  IN  HUNTINGTON ’ S  DISEASE   |  Bj ö rkqvist  et  al. 
mouse model of HD at 12 mo of age, we saw similar eleva-
tions in serum IL-6 and mKC, a mouse functional homologue 
of IL-8 (  20  ) (  Fig. 9 C  ). 12-mo YAC128 animals are pheno-
typically equivalent to early HD (  21  ), and these animals there-
fore model the human patients whose plasma was studied. 
    DISCUSSION   
  Collectively, our data show that immune activation in HD is 
widespread and detectable in peripheral plasma across disease 
stages. Key cytokines of the innate immune system are up-
regulated both centrally and peripherally, and robust changes 
secretion of IL-6 in response to stimulation compared with 
macrophages from WT mice (  Fig. 6 B  ). To test whether the 
presence of mutant huntingtin per se is suffi   cient to produce 
dysfunction, we then examined the response to LPS stimula-
tion in macrophages from the YAC18 mouse, which diff  ers 
from the YAC128 only in the length of the polyglutamine 
stretch. Excessive IL-6 release was not seen in YAC18 cells 
(  Fig. 6 C  ). To determine whether microglia, the CNS equiv-
alent of monocytes/macrophages, are also dysfunctional in 
HD, we performed LPS stimulation of microglia isolated from 
the widely used R6/2 transgenic mouse model of HD (  18  ). 
HD microglia, too, demonstrated hyperactivity in response to 
stimulation (  Fig. 6 D  ). 
  We investigated expression of infl  ammatory transcripts in 
postmortem human striatal tissue using RT-PCR and found 
markedly increased expression of IL-6, IL-8, and TNF-     in 
HD (  Fig. 7  ), mirroring the key changes seen in plasma much 
earlier in the disease.   
  To investigate the relationship between central and pe-
ripheral infl  ammatory processes, we measured IL-6 and IL-8 
in matched plasma and cerebrospinal fl  uid (CSF) samples 
from HD patients and controls using ELISA. CSF and plasma 
levels of IL-6 and IL-8 correlated closely (  Fig. 8  ; R = 0.74 
and R = 0.66, respectively; P   <   0.0001 for both).   
  We used multiplex ELISA to determine whether periph-
eral immune activation is present in serum in HD mouse 
models and found increased levels of several cytokines in the 
R6/2 transgenic mouse and the full-length knock-in model 
of HD (  Hdh    Q150/Q150  ) (  19  ). In 12-wk R6/2 mice, IL-6, IL-10, 
IL-1    , and IL-12p70 were signifi  cantly increased (  Fig. 9 A  ).   
In 22-mo knock-in   Hdh    150Q/150Q   mice, IL-6, IL-10, and IL-
12p70 were signifi  cantly elevated (  Fig. 9 B  ). In the YAC128 
    Figure 5.         Human monocytes express WT and mutant huntingtin. 
  (A) RT-QPCR studies of human monocytes obtained by fl  ow cytometry 
demonstrated huntingtin expression in 100% of monocyte samples tested 
from controls (  n   = 2) and HD patients (  n   = 3). Expression ratios are rela-
tive to B2M. Graph shows mean expression ratios with standard error 
bars. (B) PCR amplifi  cation of CAG repeat tracts from huntingtin mRNA 
reveals that HD monocytes express both WT and mutant huntingtin, sup-
porting the possibility of cell-autonomous dysfunction resulting in im-
mune activation. WT and mutant CAG repeat lengths are shown. +, 
p4G6E4.0 plasmid expressing   HTT   exon 1 with 18 CAG repeats.     
    Figure 6.         HD monocytes, macrophages, and microglia are overac-
tive when stimulated.   (A) No IL-6 was detectable in the supernatant of 
monocytes from control (  n   = 9) or premanifest HD subjects (  n   = 8) in the 
unstimulated state or after priming with IFN-    . Monocytes stimulated by 
the addition of both IFN-     and 2   μ  g/ml LPS expressed IL-6, but expression 
levels were signifi  cantly higher from HD monocytes. (B) Alveolar macro-
phages from the YAC128 HD mouse model have similarly altered function 
when stimulated. YAC128 macrophages stimulated by the addition of 
both IFN-     and 100 ng/ml LPS expressed signifi  cantly more IL-6.   n   = 3 WT 
and 4 YAC128. (C) Macrophages from YAC18 mice, which differ from 
YAC128 cells only in the number of CAG repeats, behaved no differently 
from WT cells (P = 0.231;   n   = 4 per genotype) in response to stimulation 
at the same LPS concentration, suggesting that the hyperactivity in the 
YAC128 is due to mutant huntingtin. (D) Microglia isolated from neonatal 
R6/2 mice are also hyperactive when stimulated by 10 ng/ml LPS (  n   =  4 
per group). Graphs show mean concentrations with standard error bars. 
ND, not detected. Unpaired   t   tests: *, P   <   0.05; **, P   <   0.01.     JEM VOL. 205, August 4, 2008 
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adaptive immune response. Whereas IL-6 and IL-8 produc-
tion are triggered by NF-    B activation (  7, 22  ), IL-4 and IL-
10 act to down-regulate NF-    B (  15  ). The late involvement 
of these cytokines may refl  ect an adaptive response to chronic 
immune activation, possibly involving altered interactions 
between monocytes/macrophages and Th2 cells. 
  The correlation we show between plasma and CSF levels 
of IL-6 and IL-8 links the central and peripheral immune ac-
tivation in HD. We show that IL-6 and IL-8 are increased in 
plasma and the striatum. These cytokines are not thought to 
cross the healthy blood  –  brain barrier in the acute setting (  23, 
24  ), and studies of brain penetration of specifi  c molecules in 
HD have not identifi  ed alterations of the blood  –  brain barrier 
(e.g., reference   25  ). Mutant huntingtin therefore probably 
induces parallel dysfunction in both compartments (  Fig. 10  ).   
The immune dysfunction we demonstrate in monocytes 
from premanifest HD gene carriers may refl  ect similar cen-
tral changes in HD microglia and therefore act as a window 
onto central disease pathogenesis at this very early stage in the 
disease process. Given the dramatic changes seen in striatal 
cytokine expression and the chronic nature of these changes, 
passage of cytokines from the CNS into blood is a possibil-
ity we cannot exclude, although cytokines are rapidly broken 
down (  26  ) and would likely be subject to considerable dilu-
tion in plasma. However, the presence of primary abnor-
malities of both peripheral and central cytokine-producing 
even take place in premanifest HD mutation carriers many 
years before the onset of motor abnormalities. To our knowl-
edge, the elevated IL-6 level seen in premanifest subjects with 
a mean of 16 yr until predicted clinical onset represents the 
earliest plasma abnormality identifi  ed to date in HD. The pe-
ripheral changes correlate well with clinical variables and are 
accompanied by alterations in striatal gene expression. 
  Although cytokines such as IL-4 and IL-10 are increased 
later in the disease, normal Ig levels throughout the disease 
course suggest that there is no generalized activation of the 
    Figure 7.         Altered expression of infl  ammatory transcripts in post-
mortem HD striatal tissue.   Levels of IL-6, IL-8, and TNF-     RNA  were 
signifi  cantly higher in the striatum of HD patients than in control stria-
tum. Graphs show means with standard error bars.   n   = 6 controls and 17 
HD patients (see Table S3). Unpaired   t   tests: *, P   <   0.05; ***, P   <   0.001; ****, 
P   <   0.0001.   
    Figure 8.         Correlations between matched CSF and plasma levels of 
IL-6 and IL-8.   ELISA-quantifi  ed levels in CSF and matched plasma sam-
ples correlated strongly for both IL-6 and IL-8.     
    Figure 9.         Mouse models of HD recapitulate features of human 
immune dysfunction  . Serum levels of cytokines, measured by multiplex 
ELISA, are elevated in both (A) R6/2 and (B)   Hdh  Q150Q/Q150   knock-in  mouse 
models (  n   = 9 per genotype) at end-stage. (C) In 12-mo YAC128 animals 
(equivalent to early human disease), serum IL-6 and mKC, a mouse func-
tional homologue of IL-8, are signifi  cantly increased (  n   = 3 WT and 4 
YAC128). Graphs show mean levels with standard error bars. Unpaired 
  t   tests: *, P   <   0.05; **, P   <   0.01.     1874 IMMUNE  ACTIVATION  IN  HUNTINGTON ’ S  DISEASE   |  Bj ö rkqvist  et  al. 
ever, it is possible that HD also causes diff  erences in the level 
of background immune stimulation, which could contribute 
to the later up-regulation of the adaptive immune response 
cytokines IL-4 and IL-10. 
  There is a need for markers of progression (  “  state bio-
markers  ”  ) in HD and other neurodegenerative diseases (  29  ). 
Our results suggest that infl  ammatory changes detected in pe-
ripheral plasma may be biologically relevant and mirror the 
neurodegenerative process occurring in the CNS (  Fig. 10  ). 
Indeed, combined peripheral markers of infl  ammation were 
recently suggested to be biomarkers for diagnosis and pro-
gression in Alzheimer  ’  s disease (  29  ). Remarkably, peripheral 
infl  ammatory changes may also reveal early pathogenic events 
in HD, occurring more than 15 yr before the onset of neuro-
logical manifestations. The infl  ammatory changes seen in pa-
tients are echoed in mouse models of HD. Importantly, they 
may therefore provide translational biomarkers for the use of 
HD mouse models in the development of therapeutic inter-
ventions. Finally, the mechanism of early innate immune ac-
tivation in HD warrants further study as a potential source of 
targets for disease-modifying therapies. 
  MATERIALS AND METHODS 
  Ethical approval.     All human experiments were performed in accordance 
with the declaration of Helsinki and approved by University of British 
Columbia (UBC) Clinical Research Ethics Board (Canadian patients) or 
University College London (UCL)/UCL Hospitals Joint Research Ethics 
Committee (UK patients), as appropriate. All subjects gave informed written 
consent. All animal experiments were performed in accordance with rele-
vant legislation and approved by local and national regulatory authorities 
(Institutional Review Board of the University of Washington, King  ’  s Col-
lege London Animal Care and Use Committee, or UBC Committee on 
Animal Care and the Canadian Council on Animal Care, as appropriate). 
  Collection and processing of human plasma samples.     Blood samples 
were obtained from control subjects and genetically diagnosed HD patients 
cells (monocytes/macrophages and microglia, respectively) 
suggests that parallel disease-related derangements in the pe-
riphery and CNS are the simplest explanation for these CSF  – 
plasma correlations. 
  Microglia have previously been implicated in the patho-
genesis of HD (  10  –  12  ) and are increasingly seen as key players 
in the pathogenesis of neurodegenerative diseases (  27  ). The 
increased cytokine production we observe in the CNS and 
peripherally could be caused by dysfunction of microglia and 
their counterparts, monocytes and macrophages. We show 
that monocytes from HD patients express mutant huntingtin. 
Further, we demonstrate that microglia, monocytes, and 
macrophages in HD are all hyperactive when stimulated. The 
NF-    B signaling pathway that triggers IL-6 release is known 
to be up-regulated by mutant huntingtin (  7  ), and the microg-
lial kynurenine monooxygenase pathway has been identifi  ed 
as a potential therapeutic target in HD, establishing immune 
dysfunction as a possible pathogenic pathway in HD (  28  ). 
  The functional overactivity of macrophages from 12-mo 
YAC128 mice, corresponding to early human HD, was not seen 
in macrophages from YAC18 mice, which are identical to 
YAC128 animals except for the length of the polyglutamine 
tract. This suggests that the presence of mutant huntingtin alone 
is suffi   cient to cause derangement of monocytes/macrophages. 
  Interestingly, although IL-6 is undetectable in the super-
natant of isolated human monocytes, levels of IL-6 in plasma 
are not zero in control subjects and HD patients. The same is 
true of mouse macrophages and serum. Thus, there is low-
level background cytokine production in vivo, perhaps due 
to normal cell turnover or environmental immune chal-
lenges, that is absent in vitro. A primary dysfunction of mon-
ocytes is suffi   cient to explain the increased plasma cytokine 
levels in HD, as hyperactive HD monocytes will respond ex-
cessively to this physiological background stimulation. How-
    Figure 10.         Immune activation, induced by mutant huntingtin, occurs both peripherally and centrally in HD.   A cell-autonomous effect of the 
mutant protein may be responsible for the innate immune response. The NF-    B signaling pathway that triggers IL-6 release is known to be up-regulated 
by mutant huntingtin (reference   7  ), and microglia-derived toxicity can infl  uence disease progression (references   7   and   28  ). We fi  nd that the innate im-
mune response detectable in plasma very early in the disease is strongly linked to disease progression and recapitulated in HD striatum, that human 
monocytes express mutant huntingtin, and that monocytes, macrophages, and microglia overexpress IL-6 when stimulated. Early innate immune activa-
tion could be a target in the development of disease-modifying therapies.     JEM VOL. 205, August 4, 2008 
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at 94  °  C, 25 cycles (30 s at 94  °  C, 30 s at 68  °  C, 90 s at 72  °  C), and 10 min at 
72  °  C. The FAM-tagged PCR product (1   μ  l) together with MegaBACE 
ET900 (GE Healthcare) internal size standard (0.04   μ  l) were denatured at 
94  °  C for 5 min in 9   μ  l of HiDi formamide. The run conditions were as fol-
lows: capillary size, 36 cm, Polymer-PoP-7. The run module was oven tem-
perature, 66  °  C; buff  er temperature, 35  °  C; prerun voltage, 15 kV; prerun 
time, 180 s; injection voltage, 3 kV; injection time, 20 s; fi  rst readout time, 
200 msec; second readout time, 200 msec; run voltage, 10 kV; voltage num-
ber of steps, 10; voltage step interval, 20 s; voltage tolerance, 0.6 kV; current 
stability, 10     A; ramp delay, 1 s; data delay, 120 s; run time, 2,700 s. Data 
analysis was performed using the plate manager application GeneMapper 
v5.2-3730XL. 
  Functional study of human monocytes.     Whole blood was collected in 
heparin (CP Pharmaceuticals). Leukocytes were isolated by density gradient 
centrifugation over Histopaque 1077 solution (Sigma-Aldrich). Monocytes 
were obtained by magnetic sorting to increase yield and minimize handling 
time. Mononuclear cell suspensions were labeled with anti-CD14 micro-
beads and sorted through magnetic cell separation columns (Miltenyi Biotec) 
to at least 95% purity (Fig. S1 B). Monocytes were counted, and 5   ×   10  5   cells 
per well seeded into 24-well culture plates in RPMI culture medium supple-
mented with 5% FBS, 2 mM   l-  glutamine, and 1% penicillin/streptomycin 
(Invitrogen). Cells were incubated for 16 h before stimulation. The medium 
was then changed to fresh cell culture medium with or without 10 ng/ml 
IFN-     (R  &  D Systems). For LPS stimulation, 2   μ  g/ml LPS was added to the 
medium (Sigma-Aldrich). After 24 h, supernatants were harvested from two 
separate wells for each subject/condition. The cells remaining were lysed in 
50 mM Tris, pH 8, 150 mmol NaCl, 0.5% sodium deoxycholate, and 0.5% 
Triton X-100 and assayed for total protein concentration using a protein as-
say kit according to the manufacturer  ’  s instructions (Bio-Rad Laboratories). 
IL-6 concentrations in supernatants were determined using the MSD assay 
and adjusted for total protein concentration. 
  Functional study of tissue macrophages.     Alveolar macrophages were 
isolated from 12-mo-old WT, YAC18, and YAC128 mice, all maintained 
on a pure FVB/N strain background. The YAC128 (line 53) mouse line ex-
presses high levels of full-length human huntingtin with     128 polygluta-
mine repeats and is a well-established model of HD. These mice develop an 
age-dependent phenotype similar to that seen in HD patients, including cog-
nitive defi  cits, motor dysfunction, and selective neurodegeneration; 12-mo 
mice are equivalent to early human HD (  21  ). YAC18 mice (line 212) ex-
press transgenic human WT huntingtin and do not exhibit any disease phe-
notype relative to their WT littermates. They diff  er from YAC128 mice 
only in the length of the polyglutamine tract. 
  Animals were killed using 10 mg avertine via i.p. injection. Blood was 
drawn from the inferior vena cava, and serum samples were obtained by 
two-stage centrifugation. Alveolar macrophages were extracted by intratra-
cheal infusion of ice-cold PBS (Invitrogen) followed by centrifugation and 
resuspension of extracted cells. Cells were counted and seeded at 1.5   ×   10  5   
cells/ml onto 96-well gelatin-coated plates and incubated in culture media 
containing 5% medium (RPMI 1640 [Invitrogen], 5% FBS [Cansera], and 
1% penicillin/streptomycin [Invitrogen]). After 24 h this was changed to 1% 
medium (RPMI 1640, 1% FBS, and 1% penicillin/streptomycin). Func-
tional studies were performed after an additional 24 h. The medium was 
changed to fresh 1% medium or 1% medium containing 10   μ  g/L IFN-     
(R  &  D Systems) with or without 100   μ  g/L control standard endotoxin (As-
sociates of Cape Cod). After 24 h, IL-6 concentrations were measured in su-
pernatants from two independent wells from each animal for each condition, 
using a commercial mouse IL-6 ELISA kit according to the manufacturer  ’  s 
instructions (eBioscience). Numbers of animals used in each experiment are 
given in Table S4. 
  Functional study of microglia.     Mixed primary glial cultures were pre-
pared from single brains of R6/2 mice (B6CBA-Tg(HDexon1)62Gpb/3J; 
Jackson ImmunoResearch Laboratories) as described previously (  32  ). In 
and processed as described previously (  6  ). Subjects with infl  ammatory or in-
fective conditions were excluded. A subset of subjects was assessed on the 
UHDRS (  16  ) by a neurologist experienced in assessment of HD patients. 
Subjects  ’   demographic and clinical data are given in Table S1. 
  Collection of matched CSF and blood samples.     CSF donors were re-
cruited through the UBC HD Medical Clinic. 20 HD patients and 10 con-
trol subjects, age-matched and lacking the HD mutation, were recruited 
(Table S1). Mutation-positive subjects were staged early or moderate ac-
cording to independence score. CSF and matched blood samples were ob-
tained within 1 h and plasma was extracted as described previously (  6  ). 
  Collection of mouse serum samples.     For the present experiments, 
  Hdh    Q150/Q150   knock-in and R6/2 exon 1 models that develop comparable 
and widespread molecular phenotypes (  19  ) were used. R6/2 (  18  ) and 
  Hdh    Q150/Q150   mice (original nomenclature, CHL2) (  30  ) were bred and serum 
samples were collected as described previously (  19  ). All animals had unlim-
ited access to water and breeding chow (Special Diet Services) under a 12-h 
light  –  12-h dark cycle. YAC128 mice were maintained on the FVB/N strain 
background (  21  ). Numbers and ages of animals are shown in Table S4 (avail-
able at http://www.jem.org/cgi/content/full/jem.20080178/DC1). 
  Serum and plasma analyses.     Cytokine levels were quantifi  ed using Meso 
Scale Discovery (MSD) assays as per the manufacturer  ’  s protocol and ana-
lyzed on a SECTOR 2400 instrument (MSD). The operator was unaware of 
the disease state of each sample during processing, and statistical analysis was 
performed independently. Serum levels of Igs (IgG, IgM, and IgA) were 
determined by single radial immunodiff  usion assays (The Binding Site Ltd) 
according to the manufacturer  ’  s protocol. 
  Human monocyte huntingtin expression study.     Whole blood was col-
lected from HD patients, and controls were matched for age and sex (Table S5, 
available at http://www.jem.org/cgi/content/full/jem.20080178/DC1). 
Leukocytes were isolated by density gradient centrifugation over Lympho-
prep solution (Axis-Shield). Monocytes were obtained by fl  ow cytometry. 
In brief, mononuclear cell suspensions were labeled with anti-CD45 FITC 
and anti-CD14 PE (Becton Dickinson), and viable monocytes were sorted 
fl  ow cytometrically by immunophenotype (CD45  +  /CD14  +  ) and forward 
angle light scatter signals (FACSAria high speed cell sorter; Becton Dickin-
son) to at least 95% purity (Fig. S1 A). 
  RNA was prepared from pellets of 5   ×   10  6   cells using an RNeasy mini 
kit (QIAGEN) according to the manufacturer  ’  s instructions. Quality and 
quantity of RNA was assessed using the RNA nanochip method on a Bio-
Analyzer (Agilent Technologies). RT of 1   μ  g of total RNA was performed 
in 50 mM KCl, 10 mM Tris  –  HCl, pH 9.0, 0.1% Triton X-100, 6.5 mM 
MgCl2, 10 mM DTT, 1 mM dNTPs, 10 ng/  μ  l random hexamers with 0.35 
U/  μ  l RNasin (Promega), and MMLV reverse transcription (Invitrogen) for 
10 min at 23  °  C and then 40 min at 37  °  C. The RT reaction was diluted 
10-fold in nuclease-free water (Sigma-Aldrich), and 5   μ  l was used in a 25-  μ  l 
reaction containing Precision Mastermix (PrimerDesign), 300 nM primers, 
and a 200-nM probe. Cycling conditions were as follows: 2 min at 50  °  C, 
15 min at 95  °  C, 44 cycles (1 min at 94  °  C, 1 min at 60  °  C) using the Opticon 
2 real-time PCR machine (MJ Research). The threshold used for the analysis 
was set at 0.05, and reactions were performed in triplicate for each sample. 
Primer and probe sequences are listed in Table S6 (available at http://www
.jem.org/cgi/content/full/jem.20080178/DC1). Expression of huntingtin 
was calculated using 2              CT   with     -2-microglobulin (B2M) as the reference 
(  31  ). Positive control samples with known B2M expression levels produced 
consistent results under these experimental conditions. 
  CAG repeats were measured in RNA using an ABI3730 automated 
sequencer, and all instruments and materials were obtained from Applied 
Biosystems unless indicated. The p4G6E4.0 plasmid, which expresses exon 1 of 
huntingtin with 18 CAG repeats, was used as a positive control. PCR was 
performed in AM buff  er, 10% DMSO, 200   μ  M dNTPs, 10 ng/  μ  l of primer 
with 0.5 U/  μ  l Taq polymerase (PerkinElmer). Cycling conditions were 90 s 1876 IMMUNE  ACTIVATION  IN  HUNTINGTON ’ S  DISEASE   |  Bj ö rkqvist  et  al. 
correlations across disease stage in order of diminishing R-value (IL-6, IL-8, 
IL-4, IL-10, TNF-    , and IL-5; see   Fig. 1 B  ); variables were removed from 
the model when P   <   0.05 for the logistic regression. The comparisons 
assessed were as follows: controls versus premanifest HD; controls versus all 
HD expansion  –  positive subjects; and premanifest versus manifest HD. 
  Unpaired two-tailed   t   tests were used to identify signifi  cantly diff  erent 
serum levels for each cytokine in mouse serum and to compare mRNA lev-
els (expressed as 2              CT  ) between controls and HD patients in the two gene 
expression studies. Unpaired one-tailed   t   tests were used to test the hypothe-
ses that monocytes, macrophages, and microglia produce more IL-6 than 
WT animals when stimulated with LPS. 
  Online supplemental material.     Fig. S1 shows representative fl  ow cy-
tometry plots demonstrating purity of cells obtained by fl  ow cytometry 
and magnetic sorting. Table S1 shows the characteristics of subjects in each 
human biofl  uid study. Table S2 shows plasma cytokine levels by disease 
stage measured by multiplex ELISA assay. Table S3 shows characteristics 
of subjects in the postmortem striatal expression study. Table S4 shows details 
of animals used for mouse experiments. Table S5 shows details of the sub-
jects whose blood was used for the monocyte huntingtin expression study. 
Table S6 shows the primers used for the human monocyte expression 
study. The online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20080178/DC1. 
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